Logo

American Heart Association

  2
  0


Final ID: Mo3088

Implementation and Evaluation of an Electronic Health Record Rule-Based System to Identify Heart Failure Patients Eligible for Guideline-Directed Medical Therapy

Abstract Body (Do not enter title and authors here): Background
Despite well-established benefits on morbidity and mortality, implementation of guideline-directed medical therapy (GDMT) in heart failure (HF) population remains suboptimal. Quality improvement interventions to improve GDMT uptake often necessitate labor-intensive manual chart reviews to identify eligible patients. To automate this process, we implemented and evaluated a Rule-Based System (RBS) designed to identify HF patients eligible for remote medication optimization program.
Methods
To identify symptomatic HF patients for enrollment in our Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF), an RBS was hierarchically developed to first identify HF patients meeting program criteria (Figure 1A), then exclude those with contraindications or at increased risk of adverse drug reactions. The RBS processed structured data from electronic health records (EHR) from Mass General Brigham’s enterprise data warehouse to compile a list of potentially eligible patients as per program criteria. This list was then reviewed by program staff, who manually verified patient eligibility.
Results
A total of 5,460 patients were identified by the RBS as potentially eligible, of whom 1,754 (32.1%) were confirmed as eligible on manual chart review with positive predictive value of 47.3%. Among the false positives, 25% did not meet the program criteria for symptomatic HF, 12.4% with LVEF >50% were already on SGLT2i, 11.0% were too medically complex for our program, 9.8% did not have a recorded echocardiogram within 2 years, 6.6% were receiving anticancer therapies, 4.0% had outside cardiologist, 3.9% with LVEF <50% were either on GDMT or intolerant and 23.3% had other reasons for exclusion (Figure 1B).
Discussion
These findings suggest that RBS may be a useful tool for modeling and applying guideline logic in comparison to the traditional method of querying institutional health record repositories. While the RBS demonstrated acceptable performance in mass screening for remote GDMT optimization program, future efforts should focus on improving coding and integrating the natural language processing tool for processing of clinical notes to enhance screening accuracy and efficiency.
  • Hassan, Shahzad  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Collins, Emma  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Figueroa, Christian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Ruggiero, Ryan  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Fridley, Echo  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Varugheese, Matthew  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Gabovitch, Dan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Cannon, Christopher  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Desai, Akshay  ( BRIGHAM WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Blood, Alexander  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Scirica, Benjamin  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Subramaniam, Samantha  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Wagholikar, Kavishwar  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Kumar, Sanjay  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Unlu, Ozan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Zelle, David  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Ostrominski, John  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Nichols, Hunter  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Mcpartlin, Marian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Twinning, Megan  ( Mass General Brigham , Somerville , Massachusetts , United States )
  • Author Disclosures:
    Shahzad Hassan: DO NOT have relevant financial relationships | Emma Collins: DO NOT have relevant financial relationships | Christian Figueroa: DO NOT have relevant financial relationships | Ryan Ruggiero: DO NOT have relevant financial relationships | Echo Fridley: DO NOT have relevant financial relationships | Matthew Varugheese: No Answer | Dan Gabovitch: DO NOT have relevant financial relationships | Christopher Cannon: DO have relevant financial relationships ; Researcher:Amgen, Better Therapeutics, Boehringer-Ingelheim (BI), Novo Nordisk, :Active (exists now) ; Consultant:Amryt/Chiesi, Amgen, Ascendia, Biogen, BI, BMS, CSL Behring, Eli Lilly, Janssen, Lexicon, Milestone, Pfizer, Rhoshan:Active (exists now) | Akshay Desai: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Individual Stocks/Stock Options:DTX plus:Past (completed) ; Consultant:Veristat, Zydus:Past (completed) ; Consultant:Medpace, Porter Health, Regeneron, River2Renal, Roche, Verily:Active (exists now) ; Consultant:Merck, Medtronic, Parexel, scPharmaceuticals:Past (completed) ; Consultant:Bayer, Biofourmis, Novartis:Active (exists now) ; Consultant:Avidity, Axon Therapeutics, Boston Scientific, GlaxoSmithKline:Past (completed) ; Consultant:Abbott, Alnylam, AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) | Alexander Blood: No Answer | Benjamin Scirica: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen, Better Therapeutics, Boehringer Ingelheim, Merck, NovoNordisk, Pfizer, and Verve Therapeutics:Active (exists now) ; Ownership Interest:Health [at] Scale and Aboretrum:Active (exists now) ; Consultant:Abbvie (DSMB), Amgen, AstraZeneca (DSMB), Bayer, Boehringer Ingelheim (DSMB), Elsevier Practice Update Cardiology, Hanmi (DSMB), Lexeo (DSMB), NovoNordisk, Verve Therapeutics,:Active (exists now) | Samantha Subramaniam: DO NOT have relevant financial relationships | Kavishwar Wagholikar: DO NOT have relevant financial relationships | Sanjay Kumar: DO NOT have relevant financial relationships | Ozan Unlu: DO NOT have relevant financial relationships | David Zelle: DO NOT have relevant financial relationships | John Ostrominski: DO NOT have relevant financial relationships | Hunter Nichols: DO NOT have relevant financial relationships | Marian McPartlin: DO NOT have relevant financial relationships | Megan Twinning: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

CardioTech Unleashed: Advances in Cardiovascular Diagnosis and Management

Monday, 11/18/2024 , 01:30PM - 02:30PM

Abstract Poster Session

More abstracts on this topic:
A Model-Sharing Approach for Quality Improvement of Diabetes and Cardiovascular Disease

Elligers Kyle, Pollner Meghan, Overton Katherine, Congdon Michelle, Greenway Stacey, Lambro Patricia, Sadiku Steven, Schechter Rona, Whelan John, Pressley Bianca, Sednew Renee, Duckett Sara

Aberrant Regulation of endMT in Turner Syndrome: Implications for the Pathogenesis of Congenital Cardiovascular Disease

Garcia Huitron Eric Ivan, Zhang Xiaoying, Babcock Lance, Grande-allen Kathryn, Prakash Siddharth

More abstracts from these authors:
Evaluation of an AI-Based Clinical Trial Screening Method Through a Randomized Controlled Implementation Study

Unlu Ozan, Scirica Benjamin, Aronson Samuel, Blood Alexander, Varugheese Matthew, Subramaniam Samantha, Mcpartlin Marian, Shin Jiyeon, Wagholikar Kavishwar, Oates Michael, Wang Fei, Mailly Charlotte

Manual versus AI-Assisted Clinical Trial Screening using Large-Language Models (MAPS-LLM)

Unlu Ozan, Oates Michael, Cannon Christopher, Scirica Benjamin, Wagholikar Kavishwar, Aronson Samuel, Blood Alexander, Varugheese Matthew, Shin Jiyeon, Subramaniam Samantha, Stein David, St.laurent John, Mailly Charlotte, Mcpartlin Marian, Wang Fei

You have to be authorized to contact abstract author. Please, Login
Not Available